The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Extending the use of atezolizumab and bevacizumab to a liver transplant recipient: need for a post-transplant registry
Liver Transpl. 2021 Feb 11. doi: 10.1002/lt.26011. Online ahead of print.
Najib Ben Khaled1, Daniel Roessler1, Florian P Reiter1, Max Seidensticker2, Markus Guba3, Enrico N De Toni1
Author information
1Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.
2Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
3Department of General-, Visceral- and Transplantation-Surgery, University Hospital, LMU Munich, Munich, Germany.
Abstract
We read with interest the article by Bhangui et al., who provide a model of prediction of hepatocellular carcinoma (HCC) recurrence after liver transplantation from living donor (LT) (1). The still frequent post-LT recurrence of HCC arises the controversial topic of the use of immunotherapy in liver transplant recipients; an issue, which has become of exceptional actuality after combined atezolizumab/bevacizumab have been approved for treatment of HCC.